These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26899588)

  • 21. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial.
    Huang ML; Luo BY; Hu JB; Wang SS; Zhou WH; Wei N; Hu SH; Xu Y
    Aust N Z J Psychiatry; 2012 Mar; 46(3):257-64. PubMed ID: 22391283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study.
    Shilyansky C; Williams LM; Gyurak A; Harris A; Usherwood T; Etkin A
    Lancet Psychiatry; 2016 May; 3(5):425-35. PubMed ID: 26995298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study.
    Balestri M; Calati R; Souery D; Kautzky A; Kasper S; Montgomery S; Zohar J; Mendlewicz J; Serretti A
    J Affect Disord; 2016 Jan; 189():224-32. PubMed ID: 26451508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.
    Fabbri C; Crisafulli C; Calati R; Albani D; Forloni G; Calabrò M; Martines R; Kasper S; Zohar J; Juven-Wetzler A; Souery D; Montgomery S; Mendlewicz J; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2017 Dec; 267(8):723-735. PubMed ID: 28260126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.
    Olgiati P; Serretti A; Souery D; Dold M; Kasper S; Montgomery S; Zohar J; Mendlewicz J
    J Affect Disord; 2018 Feb; 227():777-786. PubMed ID: 29254066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report.
    Nierenberg AA; Fava M; Trivedi MH; Wisniewski SR; Thase ME; McGrath PJ; Alpert JE; Warden D; Luther JF; Niederehe G; Lebowitz B; Shores-Wilson K; Rush AJ
    Am J Psychiatry; 2006 Sep; 163(9):1519-30; quiz 1665. PubMed ID: 16946176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study.
    Köhler S; Unger T; Hoffmann S; Steinacher B; Fydrich T; Bschor T
    Pharmacopsychiatry; 2013 Mar; 46(2):69-76. PubMed ID: 23093475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression.
    Bschor T; Uhr M; Baethge C; Lewitzka U; Ising M; Erbe S; Winkelmann P; Ritter D
    J Clin Psychopharmacol; 2013 Feb; 33(1):38-44. PubMed ID: 23277245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
    Sung SC; Wisniewski SR; Luther JF; Trivedi MH; Rush AJ;
    J Affect Disord; 2015 Mar; 174():157-64. PubMed ID: 25497473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.
    Cook IA; Hunter AM; Gilmer WS; Iosifescu DV; Zisook S; Burgoyne KS; Howland RH; Trivedi MH; Jain R; Greenwald S; Leuchter AF
    J Clin Psychiatry; 2013 Jan; 74(1):51-6. PubMed ID: 23419226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EEG Abnormalities Are Associated With Poorer Depressive Symptom Outcomes With Escitalopram and Venlafaxine-XR, but Not Sertraline: Results From the Multicenter Randomized iSPOT-D Study.
    Arns M; Gordon E; Boutros NN
    Clin EEG Neurosci; 2017 Jan; 48(1):33-40. PubMed ID: 26674366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes.
    Altmann H; Stahl ST; Gebara MA; Lenze EJ; Mulsant BH; Blumberger DM; Reynolds CF; Karp JF
    J Clin Psychiatry; 2020 Sep; 81(6):. PubMed ID: 32991792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study.
    Uher R; Mors O; Rietschel M; Rajewska-Rager A; Petrovic A; Zobel A; Henigsberg N; Mendlewicz J; Aitchison KJ; Farmer A; McGuffin P
    J Clin Psychiatry; 2011 Nov; 72(11):1478-84. PubMed ID: 22127194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
    Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF
    JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial.
    Kok RM; Vink D; Heeren TJ; Nolen WA
    J Clin Psychiatry; 2007 Aug; 68(8):1177-85. PubMed ID: 17854241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression.
    Holtzheimer PE; Meeks TW; Kelley ME; Mufti M; Young R; McWhorter K; Vito N; Chismar R; Quinn S; Dey S; Byrd EH; McDonald WM
    Int J Geriatr Psychiatry; 2008 Jun; 23(6):625-31. PubMed ID: 18058832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.